06.05.14
B Braun Medical U.S. and CeGaT GmbH are forming a company to enter the U.S. diagnostics market.
Globally, Diagnostic Panels, a CeGaT innovation, were first made available in 2010. The worldwide demand for molecular diagnostics is growing explosively, therefore, to supply the U.S. market with the highest quality Diagnostic Panels and molecular diagnostic services, B Braun U.S. and CeGaT have joined forces to form a U.S. company based in B. Braun Medical's headquarters, in Bethleham, PA.
The name of the new company is B Braun CeGaT LLC.
Diagnostic Panels enable CeGaT to sequence all of the genes associated with a given disease simultaneously by means of next-generation-sequencing (NGS). This approach is much faster and considerably less expensive than the classical Sanger-based
gene-by-gene sequencing which was state-of-the-art until 2010.
In addition, the probability of finding a pathogenic gene variation is significantly enhanced by the use of Diagnostic Panels, according to CeGaT. Diagnostic Panels evaluate all genes associated with the patient's phenotype. This results in a highly accurate and reliable medical report issued based on the findings of the sequencing run, the medical history of the patient and their relevant family information. This report enables the referring clinician to select the best possible therapy for each individual case.
"Pennsylvania is a fantastic centralized location for a molecular diagnostics business," Dirk Biskup, Ph.D., founder and CEO of CeGaT. "After many years of experience in the design, sequencing, and analysis of Diagnostic Panels in Germany, we can offer a real value and treatment decision support to the clinicians in the U.S."
Paul O'Connell, President of B Braun CeGaT, LLC, adds: "It is our goal to serve the U.S. healthcare market with a dedicated team and the highest possible standard in molecular diagnostics."
B. Braun Medical Inc. is focused on infusion therapy and pain management. The B.Braun Group of companies in the United States includes B.Braun, B.Braun Interventional Systems, Aesculap and CAPS. The company is based in Germany.
CeGaT is based in Tuebingen, Germany, and was founded by Biskup and Saskia Biskup, M.D., in 2009. The basis of CeGaTs technology is an established high-throughput process for the use of next-generation sequencing (NGS) in diagnostic testing and the up-to-date knowledge of hereditary genetic diseases. CeGaT has established a total of 159 Diagnostic Panels, covering more
than 1,800 individual genes. The company was awarded best German startup company in 2011 and entrepreneur of the year 2013.
Globally, Diagnostic Panels, a CeGaT innovation, were first made available in 2010. The worldwide demand for molecular diagnostics is growing explosively, therefore, to supply the U.S. market with the highest quality Diagnostic Panels and molecular diagnostic services, B Braun U.S. and CeGaT have joined forces to form a U.S. company based in B. Braun Medical's headquarters, in Bethleham, PA.
The name of the new company is B Braun CeGaT LLC.
Diagnostic Panels enable CeGaT to sequence all of the genes associated with a given disease simultaneously by means of next-generation-sequencing (NGS). This approach is much faster and considerably less expensive than the classical Sanger-based
gene-by-gene sequencing which was state-of-the-art until 2010.
In addition, the probability of finding a pathogenic gene variation is significantly enhanced by the use of Diagnostic Panels, according to CeGaT. Diagnostic Panels evaluate all genes associated with the patient's phenotype. This results in a highly accurate and reliable medical report issued based on the findings of the sequencing run, the medical history of the patient and their relevant family information. This report enables the referring clinician to select the best possible therapy for each individual case.
"Pennsylvania is a fantastic centralized location for a molecular diagnostics business," Dirk Biskup, Ph.D., founder and CEO of CeGaT. "After many years of experience in the design, sequencing, and analysis of Diagnostic Panels in Germany, we can offer a real value and treatment decision support to the clinicians in the U.S."
Paul O'Connell, President of B Braun CeGaT, LLC, adds: "It is our goal to serve the U.S. healthcare market with a dedicated team and the highest possible standard in molecular diagnostics."
B. Braun Medical Inc. is focused on infusion therapy and pain management. The B.Braun Group of companies in the United States includes B.Braun, B.Braun Interventional Systems, Aesculap and CAPS. The company is based in Germany.
CeGaT is based in Tuebingen, Germany, and was founded by Biskup and Saskia Biskup, M.D., in 2009. The basis of CeGaTs technology is an established high-throughput process for the use of next-generation sequencing (NGS) in diagnostic testing and the up-to-date knowledge of hereditary genetic diseases. CeGaT has established a total of 159 Diagnostic Panels, covering more
than 1,800 individual genes. The company was awarded best German startup company in 2011 and entrepreneur of the year 2013.